Do you support lifting the restrictions for Medicare to negotiate drug costs with pharmaceutical companies? Yes, I support.
Support lifting restrictions on Medicare negotiating drug costs with pharmaceutical companies.
Occurrences
Evidence
legacy_unverified · Source version not recorded · locator unknown
The Supreme Court rejected pharmaceutical companies' appeals, leaving Medicare's drug-price negotiation program in place and allowing the negotiations to continue.
legacy_unverified · Source version not recorded · locator unknown
Balint's office says she held a webinar with Medicare Advantage experts on October 30, 2025 to discuss changes coming to Medicare Advantage in 2026.
legacy_unverified · Source version not recorded · locator unknown
Balint joined colleagues to reintroduce the PrEP Access and Coverage Act, legislation to expand access to lifesaving HIV prevention medications.
Assessments
The promised policy objective was substantially achieved at the federal level, because Medicare’s drug-price negotiation authority was created by the Inflation Reduction Act signed on August 16, 2022, and the program remained in force during Balint’s House term, including surviving a Supreme Court challenge on May 18, 2026. But Balint took office on January 3, 2023, after the key restriction-lifting law had already passed, so she does not merit full delivery credit for the underlying outcome. The evidence shows she was engaged on health-care and medication-affordability issues during her term, which supports some credit for alignment and ongoing support, but not enough candidate-specific contribution to count as fully delivered by her.